TickerTalks
Browse all tickers →
TickerTalks›$RYTM
RYRYTM

Rhythm Pharmaceuticals, Inc.

$RYTM·$6.2B·Biotechnology·Healthcare
$87.97+1.5%YTD-18.4%1Y-19.6%
Price updated 5h ago·X counts updated 4d ago
RYRYTM
$RYTMRhythm Pharmaceuticals, Inc.
$87.97+1.45%25 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $RYTM on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

25X posts · last 7 days
Sep 28Oct 11
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $RYTM's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $RYTM — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventEvent coming upAI verdict · as of 2026-10-03

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Rhythm Pharmaceuticals with IMCIVREE Canada approval expanding the launch — Nov 3 earnings validates the specialty-pharma setup.

Rhythm Pharmaceuticals is a specialty-biopharma focused on rare-genetic-obesity disease — IMCIVREE (setmelanotide) is the central P&L driver, with the Health Canada approval expanding commercial geography.

  • The P&L is firing on growth: Q2 revenue grew 83.8% YoY to $60M at a -87.1% operating margin and EPS of -$0.83, with trailing EPS beats of 9.6% and 3.5% — the business is still unprofitable but revenue is scaling fast enough to make the profitability trajectory the central question.
  • The specific operational signal is substantive: Health Canada approval of IMCIVREE for weight management in adult and pediatric patients 4 years+ with Bardet-Biedl syndrome plus the David Meeker 50K-share sale (routine 10b5-1).

At 38% of its 52-week range going into Nov 3 earnings, the setup is coiled on validation. A clean IMCIVREE prescription-growth number plus specific commercial-launch Canada commentary is the trigger for a reclaim; a soft script number or any new-indication regulatory signal is the invalidation. The Kuehn Law investigation is standard biotech-adjacent noise.

What to watch: Nov 3 Q3 earnings — IMCIVREE prescription growth, operating margin direction, Canada commercial-launch commentary, pipeline progression, and FY27 guide. 10%+ EPS surprise plus IMCIVREE acceleration is the trigger; script softness is the invalidation.

On the calendar: 2026-11-03 — Q3 earnings

event ahead 30dregulatory expansion

Read the AI verdict on $RYTM

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Sells Imcivree (setmelanotide) for rare genetic obesity disorders caused by MC4R pathway deficiencies.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $RYTM.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $RYTM

Neutral — Sells Imcivree (setmelanotide) for rare genetic obesity disorders caused by MC4R pathway deficiencies.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+35.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-29.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-56.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-90.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
27.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-203%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
89.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.73$-0.81+9.6%
Q1 2026May 5, 2026$-0.83$-0.86+3.5%
Q4 2025Feb 26, 2026$-0.73$-0.79+7.6%
Q3 2025Nov 4, 2025$-0.82$-0.72-13.9%
Next earningsTue, Nov 3·consensus EPS $-0.71

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$60.1M+83.8%88.1%-87.1%$-0.83$-44.2M
Q4 FY25$57.3M+36.9%91.6%-82.2%$-0.73$-26.3M
Q3 FY25$51.3M+54.3%89.3%-103%$-0.82$-26.6M
Q2 FY25$48.5M+66.8%88.6%-93.4%$-0.75$-23.3M

Forward consensus

5-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$316.9M$310.2M – $328.3M-$2.98-$3.26 – -$2.6512
FY27$550.4M$509.7M – $643.3M-$0.70-$1.69 – $0.2313
FY28$868.0M$666.0M – $1.1B$2.34$0.26 – $4.1713
FY29$1.3B$1.1B – $1.5B$6.41$5.26 – $7.8611
FY30$1.7B$1.5B – $2.0B$10.10$8.30 – $12.396

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.26%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-15.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-11.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 14David P MeekerCEO50.0K sh$5.1MSellAug 31Hunter C SmithCFO62.8K sh$6.6MSellAug 13Joseph ShulmanChief Technical Officer5.1K sh$608KSellAug 13Alastair GarfieldChief Scientific Officer7.8K sh$913KSellAug 13Lee Jennifer KaydenEVP, Head of North America75.8K sh$8.9MSellAug 12Yann MazabraudEVP, Head of International57.0K sh$6.6MSellJun 22Lynn A. TetraultDirector37.0K sh$3.7MSellMay 15German Christopher PaulCorporate Controller & CAO4.6K sh$428K
+ 21 other (14 exempts · 6 awards · 1 inkind) in window

See when $RYTM insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 183
8-KPress release / Reg FDAug 48-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

RYTM filed an 8-K (Item 2.02) reporting its financial results for the second quarter ended June 30, 2026. The full text of the press release issued by, filed 2026-08-04. The actual financial figures are in the attached press release (Exhibit 99.1), not reproduced in the body excerpt. This is a material disclosure; investors should review the press release for beat/miss details and guidance.

8-KShareholder voteJun 258-K — Item 5.07: Shareholder vote
AI summary

Rhythm Pharmaceuticals held its Annual Meeting on June 24, 2026, with ~92% of 69.7M eligible votes represented. Class III directors David McGirr (53M for) and CEO David Meeker (59.9M for) were elected to serve until 2029. Shareholders ratified Ernst & Young LLP as auditor for 2026 (63.9M for) and approved executive compensation on an advisory basis (50.4M for, 11.5M against). The ~18% say-on-pay dissent rate is a notable signal of investor concern worth monitoring.

8-KPress release / Reg FDJun 158-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Rhythm Pharmaceuticals, Inc. (RYTM) made a Reg FD disclosure (Item 7.01) and reported other events (Item 8.01) in an 8-K filed June 15, 2026. Body unavailable — excerpt cuts off before the substance of the Reg FD disclosure is revealed.

+ 11 other (3 13Gs · 3 proxys · 2 10-Qs · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesityglobenewswire.com·2d agoRhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Knowzacks.com·3d agoKuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firmprnewswire.com·18d agoRhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesityglobenewswire.com·24d agoDavid Meeker Sells 50,000 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stockdefenseworld.net·30d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $RYTM on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport